280 related articles for article (PubMed ID: 31541927)
21. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
[TBL] [Abstract][Full Text] [Related]
22. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients.
van Zeeburg HJ; Snijders PJ; Wu T; Gluckman E; Soulier J; Surralles J; Castella M; van der Wal JE; Wennerberg J; Califano J; Velleuer E; Dietrich R; Ebell W; Bloemena E; Joenje H; Leemans CR; Brakenhoff RH
J Natl Cancer Inst; 2008 Nov; 100(22):1649-53. PubMed ID: 19001603
[TBL] [Abstract][Full Text] [Related]
23. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Li C; Johnson DE
Cell Cycle; 2013 Mar; 12(6):923-34. PubMed ID: 23421999
[TBL] [Abstract][Full Text] [Related]
24. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
25. Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population.
Maruyama H; Yasui T; Ishikawa-Fujiwara T; Morii E; Yamamoto Y; Yoshii T; Takenaka Y; Nakahara S; Todo T; Hongyo T; Inohara H
Cancer Sci; 2014 Apr; 105(4):409-17. PubMed ID: 24521534
[TBL] [Abstract][Full Text] [Related]
26. Combined human papillomavirus typing and TP53 mutation analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.
Daher T; Tur MK; Brobeil A; Etschmann B; Witte B; Engenhart-Cabillic R; Krombach G; Blau W; Grimminger F; Seeger W; Klussmann JP; Bräuninger A; Gattenlöhner S
Head Neck; 2018 Jun; 40(6):1109-1119. PubMed ID: 29522268
[TBL] [Abstract][Full Text] [Related]
27. Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program.
Doerstling S; Winski D; Katsoulakis E; Agarwal P; Poonnen PJ; Snowdon JL; Jackson GP; Weeraratne D; Kelley MJ; Vashistha V
J Cancer Res Clin Oncol; 2023 Jan; 149(1):69-77. PubMed ID: 36117189
[TBL] [Abstract][Full Text] [Related]
28. Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer.
Webster ALH; Sanders MA; Patel K; Dietrich R; Noonan RJ; Lach FP; White RR; Goldfarb A; Hadi K; Edwards MM; Donovan FX; Hoogenboezem RM; Jung M; Sridhar S; Wiley TF; Fedrigo O; Tian H; Rosiene J; Heineman T; Kennedy JA; Bean L; Rosti RO; Tryon R; Gonzalez AM; Rosenberg A; Luo JD; Carroll TS; Shroff S; Beaumont M; Velleuer E; Rastatter JC; Wells SI; Surrallés J; Bagby G; MacMillan ML; Wagner JE; Cancio M; Boulad F; Scognamiglio T; Vaughan R; Beaumont KG; Koren A; Imielinski M; Chandrasekharappa SC; Auerbach AD; Singh B; Kutler DI; Campbell PJ; Smogorzewska A
Nature; 2022 Dec; 612(7940):495-502. PubMed ID: 36450981
[TBL] [Abstract][Full Text] [Related]
29. Expression levels of miR-34-family microRNAs are associated with TP53 mutation status in head and neck squamous cell carcinoma.
Metheetrairut C; Chotigavanich C; Amornpichetkul K; Keskool P; Ongard S; Metheetrairut C
Eur Arch Otorhinolaryngol; 2019 Feb; 276(2):521-533. PubMed ID: 30515607
[TBL] [Abstract][Full Text] [Related]
30. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
31. Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma.
Caicedo-Granados E; Lin R; Fujisawa C; Yueh B; Sangwan V; Saluja A
Oral Oncol; 2014 Dec; 50(12):1149-56. PubMed ID: 25311433
[TBL] [Abstract][Full Text] [Related]
32. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
[TBL] [Abstract][Full Text] [Related]
33. Genome-Wide Analysis of Head and Neck Squamous Cell Carcinomas Reveals HPV, TP53, Smoking and Alcohol-Related Allele-Based Acquired Uniparental Disomy Genomic Alterations.
Tuna M; Amos CI; Mills GB
Neoplasia; 2019 Feb; 21(2):197-205. PubMed ID: 30616092
[TBL] [Abstract][Full Text] [Related]
34. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
[TBL] [Abstract][Full Text] [Related]
35. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus.
Braakhuis BJ; Snijders PJ; Keune WJ; Meijer CJ; Ruijter-Schippers HJ; Leemans CR; Brakenhoff RH
J Natl Cancer Inst; 2004 Jul; 96(13):998-1006. PubMed ID: 15240783
[TBL] [Abstract][Full Text] [Related]
36. Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines.
Nichols AC; Yoo J; Palma DA; Fung K; Franklin JH; Koropatnick J; Mymryk JS; Batada NN; Barrett JW
Arch Otolaryngol Head Neck Surg; 2012 Aug; 138(8):732-9. PubMed ID: 22911296
[TBL] [Abstract][Full Text] [Related]
37. Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50.
Chandrasekharappa SC; Chinn SB; Donovan FX; Chowdhury NI; Kamat A; Adeyemo AA; Thomas JW; Vemulapalli M; Hussey CS; Reid HH; Mullikin JC; Wei Q; Sturgis EM
Cancer; 2017 Oct; 123(20):3943-3954. PubMed ID: 28678401
[TBL] [Abstract][Full Text] [Related]
38. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
[TBL] [Abstract][Full Text] [Related]
39. Squamous cell carcinomas in patients with Fanconi anemia and dyskeratosis congenita: a search for human papillomavirus.
Alter BP; Giri N; Savage SA; Quint WG; de Koning MN; Schiffman M
Int J Cancer; 2013 Sep; 133(6):1513-5. PubMed ID: 23558727
[TBL] [Abstract][Full Text] [Related]
40. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
Anderson RT; Keysar SB; Bowles DW; Glogowska MJ; Astling DP; Morton JJ; Le P; Umpierrez A; Eagles-Soukup J; Gan GN; Vogler BW; Sehrt D; Takimoto SM; Aisner DL; Wilhelm F; Frederick BA; Varella-Garcia M; Tan AC; Jimeno A
Mol Cancer Ther; 2013 Oct; 12(10):1994-2005. PubMed ID: 23873848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
